J Cardiovasc Pharmacol. 1991 Sep;18(3):457-61. doi: 10.1097/00005344-199109000-00019.
This is a double-blind, randomized parallel-group multicenter study comprising 340 hypertensive patients. All were treated with 50 mg of atenolol once daily. If their recumbent diastolic blood pressure was greater than or equal to 95 and less than or equal to 115 mm Hg after a 4-week open run-in period, patients were randomized to receive additionally, 5, 10, or 20 mg of lisinopril once daily or placebo for a further 8-week period in a double-blind fashion. The additional effects on the trough (24-28 h after tablet intake) diastolic blood pressure of placebo and 5 mg of lisinopril were not statistically significant. Lisinopril at 10 and 20 mg reduced the recumbent diastolic blood pressure by 3.2 and 3.3 mm Hg, respectively, more than placebo (p = 0.010-0.011). The recumbent systolic blood pressure and heart rate did not change. The side effect profile of lisinopril was not different from that of placebo and adverse effects were few and mild.
这是一项双盲、随机平行组多中心研究，纳入了340名高血压患者。所有患者均接受每日一次50毫克阿替洛尔治疗。在为期4周的开放导入期后，如果患者的卧位舒张压大于或等于95毫米汞柱且小于或等于115毫米汞柱，则将患者随机分组，以双盲方式在接下来的8周内每日额外接受5毫克、10毫克或20毫克赖诺普利或安慰剂治疗。安慰剂和5毫克赖诺普利对谷值（服药后24 - 28小时）舒张压的额外影响无统计学意义。10毫克和20毫克赖诺普利使卧位舒张压分别比安慰剂降低了3.2毫米汞柱和3.3毫米汞柱（p = 0.010 - 0.011）。卧位收缩压和心率没有变化。赖诺普利的副作用情况与安慰剂无异，不良反应少且轻微。
